Unsaturated 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholines (unsaturated platelet-activating factor): aggregation of human platelets after incubation with indomethacin, creatinephosphate/creatinephosphokinase, xylocain and hirudine, and serotonin release after incubation with indomethacin.
Unsaturated platelet-activating factor (PAF) aggregates thrombocytes of healthy female volunteers and releases within 1 min up to 30.95% of the platelet serotonin. Indomethacin does not inhibit the aggregation but reduces the release of serotonin induced by unsaturated PAF in citrated platelet-rich plasma (PRP). Creatinephosphate combined with creatinephosphokinase (CP/CPK) inhibits the second phase, whereas xylocain inhibits the first and second phase of aggregation induced by unsaturated PAF. Hirudine shows no influence on the aggregation induced by unsaturated PAF.
D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D003402:Creatine Kinase / Q000378:metabolism; D005260:Female; D006629:Hirudins / Q000494:pharmacology; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology*; D008012:Lidocaine / Q000494:pharmacology; D010725:Phosphocreatine / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D012701:Serotonin / Q000378:metabolism*
D006629:Hirudins; D010972:Platelet Activating Factor; D010725:Phosphocreatine; D012701:Serotonin; D008012:Lidocaine; D003402:Creatine Kinase; D007213:Indomethacin